Overview

Arformoterol/Budesonide for COVID-19

Status:
Not yet recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, parallel, phase 2 study to evaluate the efficacy and safety of UI030 in COVID-19 patients

Phase:

Phase 2

Details

Lead Sponsor:

Korea United Pharm. Inc.